• 1
    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674.
  • 2
    Hunter T. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell 1995;80:225-236.
  • 3
    Julien SG, Dube N, Hardy S, Tremblay ML. Inside the human cancer tyrosine phosphatome. Nat Rev Cancer 2011;11:35-49.
  • 4
    Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis 2010;30:3-16.
  • 5
    Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-1255.
  • 6
    Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-1426.
  • 7
    Nault JC, Zucman Rossi J. Molecular classification of hepatocellular adenomas. Int J Hepatol 2013;2013:315947.
  • 8
    Root DE, Hacohen N, Hahn WC, Lander ES, Sabatini DM. Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods 2006;3:715-719.
  • 9
    Lo SJ, Fan LC, Tsai YF, Lin KY, Huang HL, Wang TH, et al. A novel interaction of nucleophosmin with BCL2-associated X protein regulating death evasion and drug sensitivity in human hepatoma cells. Hepatology 2013;57:1893-1905.
  • 10
    Hsieh SY, He JR, Hsu CY, Chen WJ, Bera R, Lin KY, et al. Neuregulin/erythroblastic leukemia viral oncogene homolog 3 autocrine loop contributes to invasion and early recurrence of human hepatoma. Hepatology 2011;53:504-516.
  • 11
    Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010;30:61-74.
  • 12
    Hsu IC, Tokiwa T, Bennett W, Metcalf RA, Welsh JA, Sun T, et al. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis 1993;14:987-992.
  • 13
    Zhang L, Yu Q, He J, Zha X. Study of the PTEN gene expression and FAK phosphorylation in human hepatocarcinoma tissues and cell lines. Mol Cell Biochem 2004;262:25-33.
  • 14
    Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 1980;209:497-499.
  • 15
    Sartini S, Dario B, Morelli M, Da Settimo F, La Motta C. Receptor tyrosine kinase kit and gastrointestinal stromal tumours: an overview. Curr Med Chem 2011;18:2893-2903.
  • 16
    Li P, Jayarama S, Ganesh L, Mordi D, Carr R, Kanteti P, et al. Akt-phosphorylated mitogen-activated kinase-activating death domain protein (MADD) inhibits TRAIL-induced apoptosis by blocking Fas-associated death domain (FADD) association with death receptor 4. J Biol Chem 2010;285:22713-22722.
  • 17
    Kuroda S, Fukata M, Nakagawa M, Fujii K, Nakamura T, Ookubo T, et al. Role of IQGAP1, a target of the small GTPases Cdc42 and Rac1, in regulation of E-cadherin-mediated cell-cell adhesion. Science 1998;281:832-835.
  • 18
    Rothen-Rutishauser B, Riesen FK, Braun A, Gunthert M, Wunderli-Allenspach H. Dynamics of tight and adherens junctions under EGTA treatment. J Membr Biol 2002;188:151-162.
  • 19
    Kulas DT, Zhang WR, Goldstein BJ, Furlanetto RW, Mooney RA. Insulin receptor signaling is augmented by antisense inhibition of the protein tyrosine phosphatase LAR. J Biol Chem 1995;270:2435-2438.
  • 20
    Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009;6:587-595.
  • 21
    Silverstein AM, Barrow CA, Davis AJ, Mumby MC. Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits. Proc Natl Acad Sci U S A 2002;99:4221-4226.
  • 22
    Sears R, Leone G, DeGregori J, Nevins JR. Ras enhances Myc protein stability. Mol Cell 1999;3:169-179.
  • 23
    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
  • 24
    Yim YS, Kwon Y, Nam J, Yoon HI, Lee K, Kim DG, et al. Slitrks control excitatory and inhibitory synapse formation with LAR receptor protein tyrosine phosphatases. Proc Natl Acad Sci U S A 2013;110:4057-4062.
  • 25
    Symons JR, LeVea CM, Mooney RA. Expression of the leucocyte common antigen-related (LAR) tyrosine phosphatase is regulated by cell density through functional E-cadherin complexes. Biochem J 2002;365:513-519.
  • 26
    Mander A, Hodgkinson CP, Sale GJ. Knock-down of LAR protein tyrosine phosphatase induces insulin resistance. FEBS Lett 2005;579:3024-3028.
  • 27
    Machide M, Hashigasako A, Matsumoto K, Nakamura T. Contact inhibition of hepatocyte growth regulated by functional association of the c-Met/hepatocyte growth factor receptor and LAR protein-tyrosine phosphatase. J Biol Chem 2006;281:8765-8772.
  • 28
    Krishnan H, Miller WT, Goldberg GS. SRC points the way to biomarkers and chemotherapeutic targets. Genes Cancer 2012;3:426-435.
  • 29
    Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 2008;14:152-160.
  • 30
    Lin JI, Poon CL, Harvey KF. The hippo size control pathway—ever expanding. Sci Signal 2013;6:pe4.
  • 31
    Tumaneng K, Russell RC, Guan KL. Organ size control by Hippo and TOR pathways. Curr Biol 2012;22:R368-379.
  • 32
    Zhao B, Tumaneng K, Guan KL. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol 2011;13:877-883.
  • 33
    Barry ER, Camargo FD. The Hippo superhighway: signaling crossroads converging on the Hippo/Yap pathway in stem cells and development. Curr Opin Cell Biol 2013.
  • 34
    Vermeulen L. Keeping stem cells in check: a hippo balancing act. Cell Stem Cell 2013;12:3-5.
  • 35
    Pan D. The hippo signaling pathway in development and cancer. Dev Cell 2010;19:491-505.
  • 36
    Schlegelmilch K, Mohseni M, Kirak O, Pruszak J, Rodriguez JR, Zhou D, et al. Yap1 acts downstream of alpha-catenin to control epidermal proliferation. Cell 2011;144:782-795.
  • 37
    Ribeiro PS, Josue F, Wepf A, Wehr MC, Rinner O, Kelly G, et al. Combined functional genomic and proteomic approaches identify a PP2A complex as a negative regulator of Hippo signaling. Mol Cell 2010;39:521-534.
  • 38
    Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 2010;28:1248-1250.
  • 39
    Bernabeu R, Yang T, Xie Y, Mehta B, Ma SY, Longo FM. Down-regulation of the LAR protein tyrosine phosphatase receptor is associated with increased dentate gyrus neurogenesis and an increased number of granule cell layer neurons. Mol Cell Neurosci 2006;31:723-738.
  • 40
    Niu XL, Li J, Hakim ZS, Rojas M, Runge MS, Madamanchi NR. Leukocyte antigen-related deficiency enhances insulin-like growth factor-1 signaling in vascular smooth muscle cells and promotes neointima formation in response to vascular injury. J Biol Chem 2007;282:19808-19819.
  • 41
    Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S, et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 2004;304:1164-1166.
  • 42
    Totoki Y, Tatsuno K, Yamamoto S, Arai Y, Hosoda F, Ishikawa S, et al. High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet 2011;43:464-469.
  • 43
    Bonvini P, An WG, Rosolen A, Nguyen P, Trepel J, Garcia de Herreros A, et al. Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription. Cancer Res 2001;61:1671-1677.